一种口服癌症药物AZD6738可以预防1型糖尿病
Norie Sugitani1,2,3, Hannah R Mason1, Brian T Campfield2,3
1Division of Pediatric Surgery, Department of Surgery, Pittsburgh, PA, United States.
Frontiers in immunology
|January 2, 2024
概括
一种新药,AZD6738 (ATRi),通过向自我反应的T细胞,显示出它有望预防1型糖尿病 (T1D). 延长治疗时间可以在小鼠模型中加强对T1D发病的保护.
科学领域:
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 1型糖尿病 (T1D) 是一种自身免疫性疾病,影响着数百万人,目前还没有治愈.
- 对于预防T1D发展的新型治疗策略有着至关重要的需求.
- AZD6738 (ATRi) 是一种用于治疗癌症的口服药物.
研究的目的:
- 评估AZD6738 (ATRi) 作为1型糖尿病的潜在预防疗法.
- 调查ATRi可以预防T1D的机制.
- 为了确定ATRi治疗的最佳持续时间,以预防T1D.
主要方法:
- 使用了T1D的采用转移小鼠模型.
- 用AZD6738 (ATRi) 进行治疗,治疗时间不同.
- 评估T1D发病和通过细胞的疾病转移.
主要成果:
- 增加ATRi治疗持续时间与延长对T1D发病的保护相关.
- 在小鼠模型中,5周的ATRi治疗方案完全预防了T1D.
- 与对照组不同的是,接受ATRi治疗的小鼠的囊细胞没有转移糖尿病.
结论:
- 在临床前模型中,AZD6738 (ATRi) 有效地预防T1D.
- ATRi通过诱导自我抗原激活,增殖糖尿病性T细胞的细胞死亡来起作用.
- 将ATRi重新用于T1D预防需要进一步调查.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
206
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
206
Glucagon-like Receptor Agonists
325
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
325
Dipeptidyl Peptidase 4 Inhibitors
188
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
188
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
177
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
177


